APO Research
Talk to an analyst

APO RESEARCH · REPORT

BCMA-targeted CAR-T Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global BCMA-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032

26 December 2025192 pages

Choose your research edition.

Industry ResearchBCMA-targeted CAR-T Cell Therapy Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal BCMA-targeted CAR-T Cell Therapy Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal BCMA-targeted CAR-T Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal BCMA-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal BCMA-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global BCMA-targeted CAR-T Cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for BCMA-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for BCMA-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for BCMA-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for BCMA-targeted CAR-T Cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of BCMA-targeted CAR-T Cell Therapy include Nanjing Iaso Biotherapeutics, CARsgen, Nanjing Legend Biotechnology/J&J and Bristol-Myers Squibb (Abecma), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for BCMA-targeted CAR-T Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of BCMA-targeted CAR-T Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for BCMA-targeted CAR-T Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the BCMA-targeted CAR-T Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global BCMA-targeted CAR-T Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for BCMA-targeted CAR-T Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

BCMA-targeted CAR-T Cell Therapy Segment by Company

Nanjing Iaso Biotherapeutics

CARsgen

Nanjing Legend Biotechnology/J&J

Bristol-Myers Squibb (Abecma)

BCMA-targeted CAR-T Cell Therapy Segment by Type

Abecma

Carvykti

Others

BCMA-targeted CAR-T Cell Therapy Segment by Application

Hospital

Oncology Clinic

BCMA-targeted CAR-T Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global BCMA-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of BCMA-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of BCMA-targeted CAR-T Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of BCMA-targeted CAR-T Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of BCMA-targeted CAR-T Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, BCMA-targeted CAR-T Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Abecma Major Player Table 3. Carvykti Major Player Table 4. Others Major Player Table 5. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Oncology Clinic Major Player Table 8. BCMA-targeted CAR-T Cell Therapy Industry Trends Table 9. BCMA-targeted CAR-T Cell Therapy Industry Drivers Table 10. BCMA-targeted CAR-T Cell Therapy Industry Opportunities and Challenges Table 11. BCMA-targeted CAR-T Cell Therapy Industry Restraints Table 12. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region (2021-2026) Table 15. Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region (2027-2032) Table 17. Global BCMA-targeted CAR-T Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021-2026) Table 19. Global BCMA-targeted CAR-T Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global BCMA-targeted CAR-T Cell Therapy Key Players Headquarters & Area Served Table 21. Global BCMA-targeted CAR-T Cell Therapy Players, Product Type & Application Table 22. Global BCMA-targeted CAR-T Cell Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global BCMA-targeted CAR-T Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global BCMA-targeted CAR-T Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2026) Table 29. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2027-2032) Table 30. Global BCMA-targeted CAR-T Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2026) Table 34. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2027-2032) Table 35. Nanjing Iaso Biotherapeutics Company Information Table 36. Nanjing Iaso Biotherapeutics Business Overview Table 37. Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 39. Nanjing Iaso Biotherapeutics Recent Development Table 40. CARsgen Company Information Table 41. CARsgen Business Overview Table 42. CARsgen BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. CARsgen BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 44. CARsgen Recent Development Table 45. Nanjing Legend Biotechnology/J&J Company Information Table 46. Nanjing Legend Biotechnology/J&J Business Overview Table 47. Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 49. Nanjing Legend Biotechnology/J&J Recent Development Table 50. Bristol-Myers Squibb (Abecma) Company Information Table 51. Bristol-Myers Squibb (Abecma) Business Overview Table 52. Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Product Portfolio Table 54. Bristol-Myers Squibb (Abecma) Recent Development Table 55. North America BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 56. North America BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 57. North America BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 58. North America BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 59. North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 60. North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 61. North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 62. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 63. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 64. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 65. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 66. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 67. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 68. Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 69. China BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 70. China BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 71. China BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 72. China BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 73. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 74. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 75. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 76. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 77. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 79. Asia BCMA-targeted CAR-T Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 80. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 81. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 82. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 83. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 84. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 86. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. BCMA-targeted CAR-T Cell Therapy Image Figure 2. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global BCMA-targeted CAR-T Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Abecma Image Figure 5. Carvykti Image Figure 6. Others Image Figure 7. Global BCMA-targeted CAR-T Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global BCMA-targeted CAR-T Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Oncology Clinic Image Figure 11. Global BCMA-targeted CAR-T Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global BCMA-targeted CAR-T Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global BCMA-targeted CAR-T Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global BCMA-targeted CAR-T Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 24. North America BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 25. North America BCMA-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 26. United States BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 31. Europe BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 32. Europe BCMA-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 33. Germany BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 43. China BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 44. Asia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 46. Asia BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 47. Asia BCMA-targeted CAR-T Cell Therapy Revenue Share by Region (2021-2032) Figure 48. Japan BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA BCMA-targeted CAR-T Cell Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt BCMA-targeted CAR-T Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Abecma
  • Carvykti
  • Others
Applications
  • Hospital
  • Oncology Clinic
Companies covered
  • Nanjing Iaso Biotherapeutics
  • CARsgen
  • Nanjing Legend Biotechnology/J&J
  • Bristol-Myers Squibb (Abecma)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 BCMA-targeted CAR-T Cell Therapy Market by Type
  3. 1.2.1 Global BCMA-targeted CAR-T Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Abecma
  5. 1.2.3 Carvykti
  6. 1.2.4 Others
  7. 1.3 BCMA-targeted CAR-T Cell Therapy Market by Application
  8. 1.3.1 Global BCMA-targeted CAR-T Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Oncology Clinic
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 BCMA-targeted CAR-T Cell Therapy Market Dynamics
  1. 2.1 BCMA-targeted CAR-T Cell Therapy Industry Trends
  2. 2.2 BCMA-targeted CAR-T Cell Therapy Industry Drivers
  3. 2.3 BCMA-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
  4. 2.4 BCMA-targeted CAR-T Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global BCMA-targeted CAR-T Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global BCMA-targeted CAR-T Cell Therapy Growth Trends by Region
  3. 3.2.1 Global BCMA-targeted CAR-T Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global BCMA-targeted CAR-T Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global BCMA-targeted CAR-T Cell Therapy Revenue by Players
  2. 4.1.1 Global BCMA-targeted CAR-T Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global BCMA-targeted CAR-T Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global BCMA-targeted CAR-T Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global BCMA-targeted CAR-T Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global BCMA-targeted CAR-T Cell Therapy Players, Product Type & Application
  8. 4.5 Global BCMA-targeted CAR-T Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global BCMA-targeted CAR-T Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 BCMA-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3
5 BCMA-targeted CAR-T Cell Therapy Market Size by Type
  1. 5.1 Global BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Type (2021-2032)
6 BCMA-targeted CAR-T Cell Therapy Market Size by Application
  1. 6.1 Global BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global BCMA-targeted CAR-T Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Nanjing Iaso Biotherapeutics
  2. 7.1.1 Nanjing Iaso Biotherapeutics Company Information
  3. 7.1.2 Nanjing Iaso Biotherapeutics Business Overview
  4. 7.1.3 Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Nanjing Iaso Biotherapeutics BCMA-targeted CAR-T Cell Therapy Product Portfolio
  6. 7.1.5 Nanjing Iaso Biotherapeutics Recent Developments
  7. 7.2 CARsgen
  8. 7.2.1 CARsgen Company Information
  9. 7.2.2 CARsgen Business Overview
  10. 7.2.3 CARsgen BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CARsgen BCMA-targeted CAR-T Cell Therapy Product Portfolio
  12. 7.2.5 CARsgen Recent Developments
  13. 7.3 Nanjing Legend Biotechnology/J&J
  14. 7.3.1 Nanjing Legend Biotechnology/J&J Company Information
  15. 7.3.2 Nanjing Legend Biotechnology/J&J Business Overview
  16. 7.3.3 Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Nanjing Legend Biotechnology/J&J BCMA-targeted CAR-T Cell Therapy Product Portfolio
  18. 7.3.5 Nanjing Legend Biotechnology/J&J Recent Developments
  19. 7.4 Bristol-Myers Squibb (Abecma)
  20. 7.4.1 Bristol-Myers Squibb (Abecma) Company Information
  21. 7.4.2 Bristol-Myers Squibb (Abecma) Business Overview
  22. 7.4.3 Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb (Abecma) BCMA-targeted CAR-T Cell Therapy Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb (Abecma) Recent Developments
8 North America
  1. 8.1 North America BCMA-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 8.2 North America BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America BCMA-targeted CAR-T Cell Therapy Revenue by Country
  11. 8.6.1 North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America BCMA-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe BCMA-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country
  11. 9.6.1 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe BCMA-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China BCMA-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 10.2 China BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia BCMA-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Country
  11. 11.6.1 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia BCMA-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA BCMA-targeted CAR-T Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst